By Katherine Hamilton
Nurix Therapeutics reported revenue in its fiscal second quarter more than tripled to $44.1 million, far surpassing analysts' expectations. Shares climbed 11%, to $14.59, after hours Wednesday.
Personalis expanded its work with Tempus AI on a detection test to include colorectal cancer among the diseases the test can detect. Shares rose 9%, to $7.80, in after-hours trading.
WK Kellogg could be acquired for $3 billion by candy-maker Ferrero, the Wall Street Journal reported. Shares soared 55%, to $27.05, after the market closed.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
July 09, 2025 19:09 ET (23:09 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.